WO2006002096A3 - Low doses of l-citrulline for treating diseases - Google Patents

Low doses of l-citrulline for treating diseases Download PDF

Info

Publication number
WO2006002096A3
WO2006002096A3 PCT/US2005/021811 US2005021811W WO2006002096A3 WO 2006002096 A3 WO2006002096 A3 WO 2006002096A3 US 2005021811 W US2005021811 W US 2005021811W WO 2006002096 A3 WO2006002096 A3 WO 2006002096A3
Authority
WO
WIPO (PCT)
Prior art keywords
citrulline
low doses
composition
treating diseases
infertility
Prior art date
Application number
PCT/US2005/021811
Other languages
French (fr)
Other versions
WO2006002096A2 (en
Inventor
Albert Cha
Edgar G Engleman
Original Assignee
Vivo Therapeutics Inc
Albert Cha
Edgar G Engleman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivo Therapeutics Inc, Albert Cha, Edgar G Engleman filed Critical Vivo Therapeutics Inc
Publication of WO2006002096A2 publication Critical patent/WO2006002096A2/en
Publication of WO2006002096A3 publication Critical patent/WO2006002096A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to a method of treating vascular diseases, sexual dysfunction, or infertility. The method comprises administering to a subject a composition comprising an effective amount of L-citrulline of less than 1.7 g/day. The composition is a pharmaceutical composition or a nutraceutical composition. Low doses of L-citrulline can be used in conjunction with other therapeutic agents commonly used to treat disorders.
PCT/US2005/021811 2004-06-18 2005-06-16 Low doses of l-citrulline for treating diseases WO2006002096A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58080604P 2004-06-18 2004-06-18
US60/580,806 2004-06-18
US63709204P 2004-12-17 2004-12-17
US60/637,092 2004-12-17

Publications (2)

Publication Number Publication Date
WO2006002096A2 WO2006002096A2 (en) 2006-01-05
WO2006002096A3 true WO2006002096A3 (en) 2006-05-04

Family

ID=35782276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021811 WO2006002096A2 (en) 2004-06-18 2005-06-16 Low doses of l-citrulline for treating diseases

Country Status (1)

Country Link
WO (1) WO2006002096A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7459099B2 (en) 2018-12-07 2024-04-01 インクソ エー／エス Composition for improving sexual function

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101415414B (en) * 2006-04-04 2013-06-12 雀巢产品技术援助有限公司 Use of citrulline for preparing drug for treating and correcting arginine lack in sepsis patient
BRPI0710044A2 (en) * 2006-04-04 2011-08-02 Nestec Sa treatments using citrulline
WO2008105384A1 (en) * 2007-02-26 2008-09-04 Kyowa Hakko Bio Co., Ltd. Citrulline-containing tablet
ITMI20080567A1 (en) * 2008-04-02 2009-10-03 Androsystems Srl L-CITRULLIN FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND ERECTILE DYSFUNCTION.
FR2970414B1 (en) * 2011-01-14 2013-03-22 Univ Paris Descartes PREVENTIVE ACTION OF CITRULLINE ON THE SPONTANEOUS DEVELOPMENT OF TUMORS
AT511776B1 (en) * 2011-07-26 2014-03-15 Gonadosan Gmbh USE OF CITRULLINE AND A COMBINATION PREPARATION FOR IMPROVING MALE FERTILITY
CN104857324A (en) * 2015-06-05 2015-08-26 王中杰 Traditional Chinese medicine composition for treating migraine
CU20200106A7 (en) 2018-06-20 2021-08-06 Axcella Health Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASEMIAS
CN108904729A (en) * 2018-08-23 2018-11-30 南宁协和医院 It is a kind of to treat infertile Chinese medicinal composition preparation and preparation method thereof
US11571405B2 (en) 2018-12-07 2023-02-07 Inxo A/S Compositions for improving sexual function
US20230000808A1 (en) * 2019-12-06 2023-01-05 Axcella Health Inc. Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
RU2146940C1 (en) * 1999-05-14 2000-03-27 Сергеев Алексей Вячеславович Drug for treatment of erection disorder
CN1451426A (en) * 2003-05-18 2003-10-29 漆又毛 Medicinal composition and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
RU2146940C1 (en) * 1999-05-14 2000-03-27 Сергеев Алексей Вячеславович Drug for treatment of erection disorder
CN1451426A (en) * 2003-05-18 2003-10-29 漆又毛 Medicinal composition and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7459099B2 (en) 2018-12-07 2024-04-01 インクソ エー／エス Composition for improving sexual function

Also Published As

Publication number Publication date
WO2006002096A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2008036682A3 (en) Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP1933833B8 (en) Therapy for the treatment of overactive bladder
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
BRPI0510094A (en) use of flibanserin for premenstrual treatment and other female sexual disorders
WO2006020884A3 (en) Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
WO2008050329A3 (en) Novel sirnas and methods of use thereof
EA200800007A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON NEUROACTIVE STEROID AND THEIR APPLICATION
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
BR0316753A (en) Treatment method for sexual dysfunction
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
RS52867B (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05762135

Country of ref document: EP

Kind code of ref document: A2